Scientist, Division of Virus Research and Therapeutics, CSIR-Central Drug Research Institute (CDRI), Lucknow
Do SARS-CoV-2 antibodies enhance dengue virus pathogenesis?
Host: R. Sonti
Host: R. V. Sonti
People living in tropical areas are dealing with both the COVID-19 pandemic and the most common endemic disease, such as dengue. COVID-19 and dengue co-epidemics may pose a daunting challenge to health-care systems in low- and middle-income countries. In this presentation, I will discuss about our initial data that SARS-CoV-2 immunity particularly directed to Spike (S) and Nucleocapsid (N) proteins cross-reacts with DENV structural proteins. Moreover, these antibodies did not neutralize DENVs in vitro but may have enhancement potential to cause severe dengue disease in vivo.
#ICGEBseminars
International Seminar Programme
Hundreds of videos, tens of playlists providing free scientific content worldwide